3,869 Shares in ResMed Inc. $RMD Acquired by Impax Asset Management Group plc

Impax Asset Management Group plc bought a new stake in shares of ResMed Inc. (NYSE:RMD) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 3,869 shares of the medical equipment provider’s stock, valued at approximately $1,059,000.

A number of other institutional investors and hedge funds have also modified their holdings of RMD. Johnson Investment Counsel Inc. lifted its holdings in shares of ResMed by 2.8% during the second quarter. Johnson Investment Counsel Inc. now owns 1,665 shares of the medical equipment provider’s stock valued at $430,000 after purchasing an additional 45 shares in the last quarter. Quadcap Wealth Management LLC raised its position in ResMed by 2.5% in the 2nd quarter. Quadcap Wealth Management LLC now owns 1,880 shares of the medical equipment provider’s stock worth $485,000 after buying an additional 45 shares during the last quarter. NBT Bank N A NY lifted its stake in ResMed by 22.9% during the 3rd quarter. NBT Bank N A NY now owns 252 shares of the medical equipment provider’s stock valued at $69,000 after acquiring an additional 47 shares during the period. OFI Invest Asset Management lifted its stake in ResMed by 10.4% during the 3rd quarter. OFI Invest Asset Management now owns 509 shares of the medical equipment provider’s stock valued at $139,000 after acquiring an additional 48 shares during the period. Finally, New Wave Wealth Advisors LLC boosted its holdings in shares of ResMed by 2.8% during the 3rd quarter. New Wave Wealth Advisors LLC now owns 1,899 shares of the medical equipment provider’s stock valued at $520,000 after acquiring an additional 52 shares during the last quarter. Institutional investors own 54.98% of the company’s stock.

Analyst Ratings Changes

RMD has been the subject of several research reports. Mizuho decreased their price objective on shares of ResMed from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Friday, October 31st. UBS Group reaffirmed a “buy” rating and issued a $345.00 target price on shares of ResMed in a research report on Friday, December 12th. Morgan Stanley set a $305.00 price target on ResMed in a report on Friday, October 31st. KeyCorp restated an “overweight” rating and issued a $302.00 price target on shares of ResMed in a research note on Friday, January 30th. Finally, Citigroup upped their price objective on ResMed from $330.00 to $345.00 and gave the company a “buy” rating in a research report on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $299.27.

Insider Transactions at ResMed

In other ResMed news, Director Witte Jan De sold 2,055 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $255.00, for a total transaction of $524,025.00. Following the sale, the director owned 4,261 shares in the company, valued at approximately $1,086,555. This trade represents a 32.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $251.31, for a total transaction of $502,620.00. Following the transaction, the director directly owned 64,773 shares in the company, valued at $16,278,102.63. This represents a 3.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 18,137 shares of company stock valued at $4,658,832 over the last quarter. 0.65% of the stock is currently owned by company insiders.

ResMed Stock Down 5.3%

RMD opened at $245.93 on Friday. The firm’s 50 day simple moving average is $252.63 and its two-hundred day simple moving average is $263.09. The company has a market capitalization of $35.83 billion, a PE ratio of 24.33, a PEG ratio of 1.72 and a beta of 0.87. ResMed Inc. has a 1-year low of $199.92 and a 1-year high of $293.81. The company has a current ratio of 3.06, a quick ratio of 2.32 and a debt-to-equity ratio of 0.06.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $2.81 EPS for the quarter, topping the consensus estimate of $2.68 by $0.13. ResMed had a return on equity of 25.20% and a net margin of 27.53%.The firm had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period in the prior year, the business posted $2.43 EPS. ResMed’s revenue was up 11.0% on a year-over-year basis. As a group, equities analysts forecast that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Thursday, February 12th will be given a $0.60 dividend. The ex-dividend date is Thursday, February 12th. This represents a $2.40 dividend on an annualized basis and a yield of 1.0%. ResMed’s dividend payout ratio is presently 23.74%.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.